
CLAIMS:

1. A pharmaceutical combination comprising:

(a) a B-Raf inhibitor of the formula



or a pharmaceutically acceptable salt thereof,

(b) an EGFR inhibitor, and, optionally,

(c) a PI3K-α inhibitor,


for simultaneous, separate or sequential administration.

2. A combination of claim 1 wherein the EGFR inhibitor is erlotinib or a monoclonal antibody.

3. A combination of claim 2 wherein the EGFR inhibitor is a monoclonal antibody selected from the group consisting of cetuximab and panitumumab.

4. A combination of claim 3 wherein the EGFR inhibitor is cetuximab.


5. A combination of claim 1 wherein the PI3K inhibitor is a compound of Formula I



(I),

wherein

A represents a heteroaryl selected from the group consisting of:




R1 represents one of the following substituents: (1) unsubstituted or substituted, preferably substituted C1-C7-alkyl, wherein said substituents are independently selected from one or more, preferably one to nine of the following moieties: deuterium, fluoro, or one to two of the following moieties C3-C5-cycloalkyl; (2) optionally substituted C3-C5-cycloalkyl wherein said substituents are independently selected from one or more, preferably one to four of the following moieties: deuterium, C1-C4-alkyl (preferably methyl), fluoro, cyano, aminocarbonyl; (3) optionally substituted phenyl wherein said substituents are independently selected from one or more, preferably one to two of the following moieties: deuterium, halo, cyano, C1-C7-alkyl, C1-C7-alkylamino, di(C1-C7-alkyl)amino, C1-C7-alkylaminocarbonyl, di(C1-C7-alkyl)aminocarbonyl, C1-C7-alkoxy; (4) optionally mono- or di-substituted amine; wherein said substituents are independently selected from the following moieties: deuterium, C1-C7-alkyl (which is unsubstituted or substituted by one or more substituents selected from the group of deuterium, fluoro, chloro, hydroxy), phenylsulfonyl (which is unsubstituted or substituted by one or more, preferably one, C1-C7-alkyl, C1-C7-alkoxy, di(C1-C7-alkyl)amino-C1-C7-alkoxy); (5) substituted sulfonyl; wherein said substituent is selected from the following moieties: C1-C7-alkyl (which is unsubstituted or substituted by one or more substituents selected from the group of deuterium, fluoro), pyrrolidino, (which is unsubstituted or substituted by one or more substituents selected from the group of deuterium, hydroxy, oxo; particularly one oxo); (6) fluoro, chloro;

R2 represents hydrogen;

R3 represents (1) hydrogen, (2) fluoro, chloro, (3) optionally substituted methyl, wherein said substituents are independently selected from one or more, preferably one to three of the following moieties: deuterium, fluoro, chloro, dimethylamino;

with the exception of (S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({5-[2-(tert-butyl)-pyrimidin-4-yl]-4-methyl-thiazol-2-yl}-amide).

6. A combination of claim 5 wherein the PI3K inhibitor is a compound of the formula



or a pharmaceutically acceptable salt thereof.

7. A combination of claim 6 wherein the EGFR inhibitor is cetuximab.

8. A pharmaceutical combination according to claim 1 for use in the treatment of a proliferative disease in a subject in need thereof.

9. A pharmaceutical combination according to claim 1 for use in the preparation of a medicament for the treatment of a proliferative disease.

10. A pharmaceutical combination according to claim 9 wherein the proliferative disease is characterized by a B-Raf mutation.


11. A pharmaceutical combination according to claim 10 wherein the B-Raf mutation is a V600 mutation.

12. A pharmaceutical combination according to claim 11, wherein the proliferative disease is colorectal cancer.

13. Use of the combination according to claim 1 for the manufacture of a medicament for the treatment of a proliferative disease.

14. Use of a simultaneous, separate or sequential administration of a therapeutically effective amount of

(a) a B-Raf inhibitor of the formula



or a pharmaceutically acceptable salt thereof,

(b) an EGFR inhibitor, and, optionally,

(c) a PI3K-α inhibitor,

in the manufacture of a medicament for treatment of a proliferative disease in a human patient wherein the proliferative disease is characterized by a B-Raf mutation.


15. The use according to claim 14 wherein the B-Raf mutation is a V600 mutation.

16. The use according to claim 15, wherein the proliferative disease is colorectal cancer.

CLAIMS

1. A pharmaceutical combination comprising:


(a) a B-Raf inhibitor of the formula



or a pharmaceutically acceptable salt thereof,

(b) an EGFR inhibitor, wherein the EGFR inhibitor is selected from the group consisting of erlotinib, gefitinib, cetuximab, and panitumumab, and, optionally,


(c) a PI3K-α inhibitor, wherein the PI3K-α inhibitor is a compound of Formula I



(I),

wherein

A represents a heteroaryl selected from the group consisting of:



R1 represents one of the following substituents: (1) unsubstituted or substituted C1-C7-alkyl, wherein said substituents are independently selected from one or more of the following moieties: deuterium, fluoro, or one to two of the following moieties C3-C5-cycloalkyl; (2) optionally substituted C3-C5-cycloalkyl wherein said substituents are independently selected from one or more of the following moieties: deuterium, C1-C4-alkyl, fluoro, cyano, aminocarbonyl; (3) optionally substituted phenyl

wherein said substituents are independently selected from one or more of the following moieties: deuterium, halo, cyano, C1-C7-alkyl, C1-C7-alkylamino, di(C1-C7-alkyl)amino, C1-C7-alkylaminocarbonyl, di(C1-C7-alkyl)aminocarbonyl, C1-C7-alkoxy; (4) optionally mono- or di-substituted amine; wherein said substituents are independently selected from the following moieties: deuterium, C1-C7-alkyl (which is unsubstituted or substituted by one or more substituents selected from the group of deuterium, fluoro, chloro, hydroxy), phenylsulfonyl (which is unsubstituted or substituted by one or more C1-C7-alkyl, C1-C7-alkoxy, di(C1-C7-alkyl)amino-C1-C7-alkoxy); (5) substituted sulfonyl; wherein said substituent is selected from the following moieties: C1-C7-alkyl (which is unsubstituted or substituted by one or more substituents selected from the group of deuterium, fluoro), pyrrolidino, (which is unsubstituted or substituted by one or more substituents selected from the group of deuterium, hydroxy, oxo); (6) fluoro, chloro;

R2 represents hydrogen;

R3 represents (1) hydrogen, (2) fluoro, chloro, (3) optionally substituted methyl, wherein said substituents are independently selected from one or more of the following moieties: deuterium, fluoro, chloro, dimethylamino;


with the exception of (S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({5-[2-(tert-butyl)-pyrimidin-4-yl]-4-methyl-thiazol-2-yl}-amide).for simultaneous, separate or sequential administration.

2. A combination of claim 1 wherein the EGFR inhibitor is erlotinib.

3. A combination of claim 1 wherein the EGFR inhibitor is cetuximab or panitumumab.

4. A combination of claim 1 wherein the EGFR inhibitor is cetuximab.

5. A combination of claim 1 wherein the PI3K-α inhibitor is a compound of the formula



6. A combination of claim 5 wherein the EGFR inhibitor is cetuximab.

7. A pharmaceutical combination according to claim 1 for use in the treatment of a proliferative disease in a subject in need thereof.

8. A pharmaceutical combination according to claim 1 for use in the preparation of a medicament for the treatment of a proliferative disease, wherein the proliferative disease is characterized by a B-Raf mutation.


9. A pharmaceutical combination according to claim 8 wherein the B-Raf mutation is a V600 mutation.

10. A pharmaceutical combination according to claim 9, wherein the proliferative disease is colorectal cancer.

11. Use of the combination according to claim 1 for the manufacture of a medicament for the treatment of a proliferative disease, wherein the proliferative disease is characterized by a B-Raf mutation.

12. Use of a simultaneous, separate or sequential administration of a therapeutically effective amount of


(a) a B-Raf inhibitor of the formula



or a pharmaceutically acceptable salt thereof,

(b) an EGFR inhibitor, wherein the EGFR inhibitor is selected from the group consisting of erlotinib, gefitinib, cetuximab, and panitumumab and, optionally,


(c) a PI3K-α inhibitor, wherein the PI3K-α inhibitor is a compound of Formula I



(I),

wherein

A represents a heteroaryl selected from the group consisting of:



R1 represents one of the following substituents: (1) unsubstituted or substituted C1-C7-alkyl, wherein said substituents are independently selected from one or more of the following moieties: deuterium, fluoro, or one to two of the following moieties C3-C5-cycloalkyl; (2) optionally substituted C3-C5-cycloalkyl wherein said substituents are independently selected from one or more of the following moieties: deuterium, C1-C4-alkyl, fluoro, cyano, aminocarbonyl; (3) optionally substituted phenyl wherein said substituents are independently selected from one or more of the following moieties: deuterium, halo, cyano, C1-C7-alkyl, C1-C7-alkylamino, di(C1-C7-alkyl)amino, C1-C7-alkylaminocarbonyl, di(C1-C7-alkyl)aminocarbonyl, C1-C7-alkoxy; (4) optionally mono- or di-substituted amine; wherein said substituents are independently selected from the following moieties: deuterium, C1-C7-alkyl (which is unsubstituted or substituted by one or more substituents selected from the group of deuterium, fluoro, chloro, hydroxy), phenylsulfonyl (which is unsubstituted or substituted by one or more C1-C7-alkyl, C1-C7-alkoxy, di(C1-C7-alkyl)amino-C1-C7-alkoxy); (5) substituted sulfonyl; wherein said substituent is selected from the following moieties: C1-C7-alkyl (which is unsubstituted or substituted by one or more substituents selected from the group of deuterium, fluoro), pyrrolidino, (which is unsubstituted or substituted by one or more substituents selected from the group of deuterium, hydroxy, oxo); (6) fluoro, chloro;

R2 represents hydrogen;

R3 represents (1) hydrogen, (2) fluoro, chloro, (3) optionally substituted methyl, wherein said substituents are independently selected from one or more of the following moieties: deuterium, fluoro, chloro, dimethylamino;

with the exception of (S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({5-[2-(tert-butyl)-pyrimidin-4-yl]-4-methyl-thiazol-2-yl}-amide)

in the manufacture of a medicament for treatment of a proliferative disease in a human patient wherein the proliferative disease is characterized by a B-Raf mutation.

13. The use according to claim 12, wherein the B-Raf mutation is a V600 mutation.

14. The use according to claim 13, wherein the proliferative disease is colorectal cancer.

15. The pharmaceutical combination of claim 1 wherein the PI3K-α inhibitor is a compound of Formula I, wherein

R1 represents one of the following substituents: (1) substituted C1-C7-alkyl, wherein said substituents are independently selected from one to nine of the following moieties: deuterium, fluoro, or

one to two of the following moieties C3-C5-cycloalkyl; (2) optionally substituted C3-C5-cycloalkyl wherein said substituents are independently selected from one to four of the following moieties: deuterium, methyl, fluoro, cyano, aminocarbonyl; (3) optionally substituted phenyl wherein said substituents are independently selected from one to two of the following moieties: deuterium, halo, cyano, C1-C7-alkyl, C1-C7-alkylamino, di(C1-C7-alkyl)amino, C1-C7-alkylaminocarbonyl, di(C1-C7-alkyl)aminocarbonyl, C1-C7-alkoxy; (4) optionally mono- or di- substituted amine; wherein said substituents are independently selected from the following moieties: deuterium, C1-C7-alkyl (which is unsubstituted or substituted by one or more substituents selected from the group of deuterium, fluoro, chloro, hydroxy), phenylsulfonyl (which is unsubstituted or substituted by one C1-C7-alkyl, C1-C7-alkoxy, di(C1-C7-alkyl)amino-C1-C7-alkoxy); (5) substituted sulfonyl; wherein said substituent is selected from the following moieties: C1-C7-alkyl (which is unsubstituted or substituted by one or more substituents selected from the group of deuterium, fluoro), pyrrolidino, (which is unsubstituted or substituted by one oxo); (6) fluoro, chloro; and

R3 represents (1) hydrogen, (2) fluoro, chloro, (3) optionally substituted methyl, wherein said substituents are independently selected one to three of the following moieties: deuterium, fluoro, chloro, dimethylamino.